Beryl Capital Management’s Blueprint Medicines BPMC Stock Holding History

Beryl Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,067,224	Closed	-$137M	–	10
2025 Q2	$137M	Buy	+1,067,224	New	+$111M	20.6%	1

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Beryl Capital Management's BPMC Position: Q3 2025 in Review

Beryl Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,067,224 shares — an estimated $137M sold.

Beryl Capital Management first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $137M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Beryl Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Beryl Capital Management sold 1,067,224 Blueprint Medicines shares in Q3 2025, an estimated $137M.
Beryl Capital Management first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Beryl Capital Management's Blueprint Medicines position peaked at $137M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Beryl Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.